Key result
ANGPTL4 deficiency cuts cisplatin and doxorubicin IC50 by ~50% and enhances metastatic cancer cell apoptosis.
Why the study?
The mechanism linking epithelial-mesenchymal transition to multidrug resistance in cancer cells remains unclear, particularly regarding metabolic flexibility and ABC transporter regulation.
Does suppression of ANGPTL4 sensitize metastatic cancer cells to chemotherapy drugs?
Does suppression of ANGPTL4 sensitize metastatic cancer cells to chemotherapy drugs?
Suppressing ANGPTL4 deprives EMT cancer cells of energy, reducing ABC transporter expression and potentially overcoming chemoresistance.
No takes yet. Share an insight, caveat, or question.
May enhance cisplatin sensitivity in metastatic models; leaves open clinical translation and human trials.
Lim et al. (2018) conducted a letter in Metastatic cancer and multidrug resistance. ANGPTL4 suppression vs. Control (ANGPTL4 competent) was evaluated on IC50 of anti-tumor drugs and apoptosis. ANGPTL4 deficiency reduced the IC50 of cisplatin and doxorubicin by approximately 50% and enhanced apoptosis of metastatic cancer cells.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: